

# Martti Antero Frkkil

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2514777/martti-antero-farkkila-publications-by-citations.pdf>

**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

167  
papers

9,077  
citations

45  
h-index

93  
g-index

186  
ext. papers

12,936  
ext. citations

6.4  
avg, IF

5.57  
L-index

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 167 | The mutational constraint spectrum quantified from variation in 141,456 humans. <i>Nature</i> , <b>2020</b> , 581, 434-443  | 50.4 | 2278      |
| 166 | Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. <i>Lancet, The</i> , <b>2012</b> , 380, 1909-15                          | 40   | 394       |
| 165 | Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. <i>Inflammatory Bowel Diseases</i> , <b>2008</b> , 14, 40-6                             | 4.5  | 338       |
| 164 | Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. <i>Gastroenterology</i> , <b>2010</b> , 139, 1198-206  | 13.3 | 278       |
| 163 | Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. <i>Nature Genetics</i> , <b>2013</b> , 45, 670-5   | 36.3 | 267       |
| 162 | A structural variation reference for medical and population genetics. <i>Nature</i> , <b>2020</b> , 581, 444-451  | 50.4 | 223       |
| 161 | Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , <b>2017</b> , 152, 1975-1984.e8   | 13.3 | 219       |
| 160 | Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2008</b> , 14, 1392-8  | 4.5  | 178       |
| 159 | Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. <i>Hepatology</i> , <b>2008</b> , 47, 1837-45  | 11.2 | 171       |
| 158 | IL-23/IL-17 immunity as a hallmark of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2008</b> , 14, 1175-84   | 4.5  | 156       |
| 157 | Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 325-336 | 18.8 | 153       |
| 156 | Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. <i>Hepatology</i> , <b>2004</b> , 40, 1379-86   | 11.2 | 141       |
| 155 | Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , <b>2017</b> , 49, 269-273                      | 36.3 | 140       |
| 154 | Ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 549-558   | 13.4 | 138       |
| 153 | Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF- $\alpha$ blocking agents. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 2011-7                                 | 4.5  | 132       |
| 152 | Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. <i>Scandinavian Journal of Gastroenterology</i> , <b>2010</b> , 45, 325-31                                    | 2.4  | 126       |
| 151 | Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2012</b> , 47, 528-37                 | 2.4  | 119       |

|     |  |      |     |
|-----|--|------|-----|
| 150 | Esophageal morbidity and function in adults with repaired esophageal atresia with tracheoesophageal fistula: a population-based long-term follow-up. <i>Annals of Surgery</i> , <b>2010</b> , 251, 1167-73 <sup>8</sup>                              | 7.8  | 109 |
| 149 | Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. <i>Hepatology</i> , <b>2018</b> , 67, 2141-2149   | 11.2 | 98  |
| 148 | Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. <i>Endoscopy</i> , <b>2017</b> , 49, 588-608               | 3.4  | 94  |
| 147 | Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD. <i>Inflammatory Bowel Diseases</i> , <b>2010</b> , 16, 2131-6   | 4.5  | 89  |
| 146 | Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , <b>2016</b> , 150, 380-8.e4           | 13.3 | 85  |
| 145 | Helsinki alert of biodiversity and health. <i>Annals of Medicine</i> , <b>2015</b> , 47, 218-25  | 1.5  | 79  |
| 144 | Achievement of deep remission during scheduled maintenance therapy with TNF- $\alpha$ -blocking agents in IBD. <i>Journal of Crohn's and Colitis</i> , <b>2013</b> , 7, 730-5  | 1.5  | 79  |
| 143 | Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , <b>2011</b> , 5, 484-98    | 1.5  | 78  |
| 142 | Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. <i>Hepatology</i> , <b>2015</b> , 62, 188-97  | 11.2 | 76  |
| 141 | Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. <i>Hepatology</i> , <b>2010</b> , 52, 430-5  | 11.2 | 69  |
| 140 | Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. <i>Scandinavian Journal of Gastroenterology</i> , <b>2012</b> , 47, 778-84                                      | 2.4  | 68  |
| 139 | Does fecal calprotectin predict short-term relapse after stopping TNF- $\alpha$ -blocking agents in inflammatory bowel disease patients in deep remission?. <i>Journal of Crohn's and Colitis</i> , <b>2015</b> , 9, 33-40                           | 1.5  | 66  |
| 138 | Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , <b>2011</b> , 5, 41-7   | 1.5  | 64  |
| 137 | Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data. <i>International Journal of Cancer</i> , <b>2014</b> , 134, 189-96              | 7.5  | 63  |
| 136 | Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 1265-1281 | 13.4 | 62  |
| 135 | Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. <i>Scandinavian Journal of Gastroenterology</i> , <b>2013</b> , 48, 1405-13  | 2.4  | 58  |
| 134 | Association of IL23R, TNFRSF1A, and HLA-DRB1*0103 allele variants with inflammatory bowel disease phenotypes in the Finnish population. <i>Inflammatory Bowel Diseases</i> , <b>2008</b> , 14, 1118-24   | 4.5  | 57  |
| 133 | Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2013</b> , 48, 543-51  | 2.4  | 56  |

|     |  |      |    |
|-----|--|------|----|
| 132 | Outcome after discontinuation of TNF $\alpha$ -blocking therapy in patients with inflammatory bowel disease in deep remission. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 1021-8                                 | 4.5  | 56 |
| 131 | Transcript expression-aware annotation improves rare variant interpretation. <i>Nature</i> , <b>2020</b> , 581, 452-458  | 50.4 | 55 |
| 130 | Prevalence and incidence of primary biliary cirrhosis are increasing in Finland. <i>Scandinavian Journal of Gastroenterology</i> , <b>2007</b> , 42, 1347-53   | 2.4  | 54 |
| 129 | Evaluating drug targets through human loss-of-function genetic variation. <i>Nature</i> , <b>2020</b> , 581, 459-464   | 50.4 | 53 |
| 128 | IL23R in the Swedish, Finnish, Hungarian and Italian populations: association with IBD and psoriasis, and linkage to celiac disease. <i>BMC Medical Genetics</i> , <b>2009</b> , 10, 8                                       | 2.1  | 53 |
| 127 | Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. <i>Hepatology</i> , <b>2017</b> , 65, 907-919   | 11.2 | 50 |
| 126 | High and increasing prevalence of inflammatory bowel disease in Finland with a clear North-South difference. <i>Journal of Crohn's and Colitis</i> , <b>2013</b> , 7, e256-62  | 1.5  | 47 |
| 125 | Quality of life following laparoscopic Nissen fundoplication: assessing short-term and long-term outcomes. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 3810-8   | 5.6  | 47 |
| 124 | Mortality and causes of death in patients with inflammatory bowel disease: a nationwide register study in Finland. <i>Journal of Crohn's and Colitis</i> , <b>2014</b> , 8, 1088-96  | 1.5  | 45 |
| 123 | Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-Up of Population Cohorts. <i>Hepatology</i> , <b>2020</b> , 71, 835-848   | 11.2 | 45 |
| 122 | No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , <b>2018</b> , 155, 752-759.e5  | 13.3 | 44 |
| 121 | PepT1 oligopeptide transporter (SLC15A1) gene polymorphism in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , <b>2009</b> , 15, 1562-9  | 4.5  | 44 |
| 120 | Societal costs for irritable bowel syndrome--a population based study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2010</b> , 45, 582-91  | 2.4  | 43 |
| 119 | Magnetic resonance imaging is superior to computed tomography and ultrasonography in imaging infectious liver foci in acute leukaemia. <i>European Journal of Haematology</i> , <b>1996</b> , 56, 82-7                       | 3.8  | 43 |
| 118 | Comorbidity and use of health-care services among irritable bowel syndrome sufferers. <i>Scandinavian Journal of Gastroenterology</i> , <b>2007</b> , 42, 799-806  | 2.4  | 43 |
| 117 | Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 203, 1748-52 | 7    | 42 |
| 116 | A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. <i>Nature Communications</i> , <b>2016</b> , 7, 12342  | 17.4 | 41 |
| 115 | Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population. <i>PLoS Genetics</i> , <b>2018</b> , 14, e1007329  | 6    | 41 |

|     |  |      |    |
|-----|--|------|----|
| 114 | Bile microbiota in primary sclerosing cholangitis: Impact on disease progression and development of biliary dysplasia. <i>PLoS ONE</i> , <b>2017</b> , 12, e0182924  | 3.7  | 40 |
| 113 | Increasing incidence of inflammatory bowel diseases between 2000 and 2007: a nationwide register study in Finland. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 555-61                             | 4.5  | 40 |
| 112 | Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. <i>Liver International</i> , <b>2017</b> , 37, 1554-1561                             | 7.9  | 39 |
| 111 | Impact of demographic factors, medication and symptoms on disease-specific quality of life in inflammatory bowel disease. <i>Quality of Life Research</i> , <b>2009</b> , 18, 961-9                          | 3.7  | 38 |
| 110 | Genetic analysis in Finnish families with inflammatory bowel disease supports linkage to chromosome 3p21. <i>European Journal of Human Genetics</i> , <b>2001</b> , 9, 328-34                                | 5.3  | 37 |
| 109 | Patient-controlled sedation with propofol and remifentanyl for ERCP: a randomized, controlled study. <i>Gastrointestinal Endoscopy</i> , <b>2011</b> , 73, 260-6   | 5.2  | 36 |
| 108 | Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 1214-1222                                       | 13.4 | 34 |
| 107 | Capsule endoscopy in pediatric patients: technique and results in our first 100 consecutive children. <i>Scandinavian Journal of Gastroenterology</i> , <b>2011</b> , 46, 1138-43                            | 2.4  | 34 |
| 106 | Infliximab-induced skin manifestations in patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 563-71   | 2.4  | 31 |
| 105 | Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. <i>Hepatology</i> , <b>2014</b> , 59, 2131-9                    | 11.2 | 31 |
| 104 | Unexpectedly High Prevalence of Common Variable Immunodeficiency in Finland. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1190  | 8.4  | 30 |
| 103 | Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. <i>PLoS ONE</i> , <b>2012</b> , 7, e29370   | 3.7  | 30 |
| 102 | A randomized comparison of target-controlled propofol infusion and patient-controlled sedation during ERCP. <i>Endoscopy</i> , <b>2013</b> , 45, 915-9   | 3.4  | 28 |
| 101 | Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , <b>2018</b> , 67, 1517-1524   | 19.2 | 28 |
| 100 | Screening primary sclerosing cholangitis and biliary dysplasia with endoscopic retrograde cholangiography and brush cytology: risk factors for biliary neoplasia. <i>Endoscopy</i> , <b>2016</b> , 48, 432-9 | 3.4  | 25 |
| 99  | Endoscopic monitoring of infliximab therapy in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2011</b> , 17, 947-53  | 4.5  | 24 |
| 98  | Lipid metabolism in bile acid malabsorption. <i>Annals of Medicine</i> , <b>1990</b> , 22, 5-13  | 1.5  | 24 |
| 97  | A High Prevalence of Gastrointestinal Manifestations in Common Variable Immunodeficiency. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 648-655   | 0.7  | 23 |

|    |  |      |    |
|----|--|------|----|
| 96 | Health-related quality of life in inflammatory bowel disease measured with the generic 15D instrument. <i>Quality of Life Research</i> , <b>2010</b> , 19, 919-28  | 3.7  | 23 |
| 95 | Biliary dysplasia in patients with primary sclerosing cholangitis: additional value of DNA ploidity. <i>Liver International</i> , <b>2012</b> , 32, 783-9  | 7.9  | 22 |
| 94 | Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: A nationwide register-based cohort study in Finland. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 1294-1299                                    | 3.3  | 21 |
| 93 | Medication use among inflammatory bowel disease patients: excessive consumption of antidepressants and analgesics. <i>Scandinavian Journal of Gastroenterology</i> , <b>2013</b> , 48, 42-50   | 2.4  | 21 |
| 92 | Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. <i>Liver International</i> , <b>2008</b> , 28, 787-97  | 7.9  | 21 |
| 91 | Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study. <i>PLoS ONE</i> , <b>2017</b> , 12, e0179764   | 3.7  | 21 |
| 90 | Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 3123-3130   | 4    | 20 |
| 89 | PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. <i>BMC Medical Genetics</i> , <b>2012</b> , 13, 82   | 2.1  | 20 |
| 88 | Effect of smoking on gastric histology in Helicobacter pylori-positive gastritis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2008</b> , 43, 1177-83  | 2.4  | 20 |
| 87 | Finnish patients with inflammatory bowel disease have fewer symptoms and are more satisfied with their treatment than patients in the previous European survey. <i>Scandinavian Journal of Gastroenterology</i> , <b>2008</b> , 43, 821-30 | 2.4  | 18 |
| 86 | Metabolism of cholesterol and low- and high-density lipoproteins in primary biliary cirrhosis: Cholesterol absorption and synthesis related to lipoprotein levels and their kinetics. <i>Hepatology</i> , <b>1995</b> , 21, 89-95          | 11.2 | 18 |
| 85 | Serum cholestanol, cholesterol precursors, and plant sterols during placebo-controlled treatment of primary biliary cirrhosis with ursodeoxycholic acid or colchicine. <i>Hepatology</i> , <b>1995</b> , 21, 1261-1268                     | 11.2 | 18 |
| 84 | Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. <i>Scandinavian Journal of Gastroenterology</i> , <b>2020</b> , 55, 74-81                                    | 2.4  | 18 |
| 83 | Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis. <i>United European Gastroenterology Journal</i> , <b>2016</b> , 4, 562-9  | 5.3  | 17 |
| 82 | Interaction Between Alcohol Use and Metabolic Risk Factors for Liver Disease: A Critical Review of Epidemiological Studies. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2020</b> , 44, 384-403                              | 3.7  | 17 |
| 81 | A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 321-329   | 13.4 | 17 |
| 80 | Novel CARD15/NOD2 mutations in Finnish patients with Crohn's disease and their relation to phenotypic variation in vitro and in vivo. <i>Inflammatory Bowel Diseases</i> , <b>2008</b> , 14, 176-85  | 4.5  | 16 |
| 79 | A case report: ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis. <i>Journal of Crohn's and Colitis</i> , <b>2012</b> , 6, 724-7                                    | 1.5  | 15 |

|    |   |      |    |
|----|---|------|----|
| 78 | Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. <i>Hepatology</i> , <b>2020</b> , 72, 1253-1266   | 11.2 | 15 |
| 77 | Incidence, survival and cause-specific mortality in alcoholic liver disease: a population-based cohort study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 961-6   | 2.4  | 15 |
| 76 | Drinking and Obesity: Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Interactions. <i>Seminars in Liver Disease</i> , <b>2020</b> , 40, 154-162   | 7.3  | 14 |
| 75 | Surveillance of primary sclerosing cholangitis with ERC and brush cytology: risk factors for cholangiocarcinoma. <i>Scandinavian Journal of Gastroenterology</i> , <b>2017</b> , 52, 242-249  | 2.4  | 14 |
| 74 | Health-related quality of life among patients with primary sclerosing cholangitis. <i>Liver International</i> , <b>2015</b> , 35, 2194-201  | 7.9  | 14 |
| 73 | Cyclosporin Versus Infliximab in Severe Acute Ulcerative Colitis Refractory to Intravenous Steroids: A Randomized Trial. <i>Gastroenterology</i> , <b>2011</b> , 140, S-112   | 13.3 | 14 |
| 72 | Reducing carcinogenic acetaldehyde exposure in the achlorhydric stomach with cysteine. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2011</b> , 35, 516-22   | 3.7  | 14 |
| 71 | Dendritic cells from Crohn's disease patients show aberrant STAT1 and STAT3 signaling. <i>PLoS ONE</i> , <b>2013</b> , 8, e70738  | 3.7  | 14 |
| 70 | Histologic surveillance after liver transplantation due to autoimmune hepatitis. <i>Clinical Transplantation</i> , <b>2017</b> , 31, e12936   | 3.8  | 13 |
| 69 | Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. <i>Scandinavian Journal of Gastroenterology</i> , <b>2013</b> , 48, 839-47                         | 2.4  | 13 |
| 68 | Nizatidine and gastric emptying in functional dyspepsia. <i>Digestive Diseases and Sciences</i> , <b>2008</b> , 53, 352-7   | 4    | 13 |
| 67 | Impact of obesity on the bioavailability of peginterferon- $\alpha$ 2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. <i>PLoS ONE</i> , <b>2012</b> , 7, e37521   | 3.7  | 13 |
| 66 | Risk of Esophageal Adenocarcinoma After Antireflux Surgery in Patients With Gastroesophageal Reflux Disease in the Nordic Countries. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1576-1582  | 13.4 | 12 |
| 65 | The role of magnetic resonance imaging and endoscopic retrograde cholangiography in the evaluation of disease activity and severity in primary sclerosing cholangitis. <i>Liver International</i> , <b>2018</b> , 38, 2329-2339           | 7.9  | 12 |
| 64 | Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNF $\alpha$ -blocking agents. <i>Scandinavian Journal of Gastroenterology</i> , <b>2017</b> , 52, 284-290                          | 2.4  | 12 |
| 63 | Piloting gender-oriented colorectal cancer screening with a faecal immunochemical test: population-based registry study from Finland. <i>BMJ Open</i> , <b>2021</b> , 11, e046667   | 3    | 12 |
| 62 | Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. <i>Hepatology</i> , <b>2008</b> , 48, 695 | 11.2 | 11 |
| 61 | Does oral $\alpha$ -galactosidase relieve irritable bowel symptoms?. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 16-21  | 2.4  | 10 |

|    |  |      |    |
|----|--|------|----|
| 60 | Cohort profile: the Nordic Antireflux Surgery Cohort (NordASCo). <i>BMJ Open</i> , <b>2017</b> , 7, e016505  | 3    | 10 |
| 59 | Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 337-43  | 2.4  | 10 |
| 58 | Malignancies in inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , <b>2015</b> , 50, 81-9   | 2.4  | 10 |
| 57 | In Crohn's Disease, Anti-TNF- $\alpha$ Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells. <i>ISRN Gastroenterology</i> , <b>2012</b> , 2012, 505432  |      | 10 |
| 56 | Environmental Risk Factors of Pediatric-Onset Primary Sclerosing Cholangitis and Autoimmune Hepatitis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2016</b> , 62, 437-42   | 2.8  | 10 |
| 55 | Fecal Calprotectin Test Performed at Home: A Prospective Study of Pediatric Patients With Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2018</b> , 66, 926-931   | 2.8  | 10 |
| 54 | Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease. <i>European Journal of Clinical Investigation</i> , <b>2016</b> , 46, 825-32  | 4.6  | 9  |
| 53 | Is home monitoring of inflammatory bowel disease feasible? A randomized controlled study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 849-854  | 2.4  | 9  |
| 52 | Biliary Anomalies in Patients With HNF1B Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 2075-2082  | 5.6  | 9  |
| 51 | Serum lipopolysaccharides predict advanced liver disease in the general population. <i>JHEP Reports</i> , <b>2019</b> , 1, 345-352   | 10.3 | 9  |
| 50 | Combined Effects of Alcohol and Metabolic Disorders in Patients With Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 995-997.e2   | 6.9  | 9  |
| 49 | Genetic and lifestyle risk factors for advanced liver disease among men and women. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 291-298   | 4    | 9  |
| 48 | Effect of steatosis and inflammation on liver fibrosis in chronic hepatitis C. <i>Liver International</i> , <b>2009</b> , 29, 153-8  | 7.9  | 8  |
| 47 | Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155142                            | 3.7  | 8  |
| 46 | Cancer incidence among alcoholic liver disease patients in Finland: A retrospective registry study during years 1996-2013. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 2616-21   | 7.5  | 8  |
| 45 | Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 707-711 | 2.4  | 7  |
| 44 | Outcome of inflammatory bowel disease patients treated with TNF- $\alpha$ inhibitors: two-year follow-up. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 1476-1481  | 2.4  | 7  |
| 43 | Esophageal Adenocarcinoma After Antireflux Surgery in a Cohort Study From the 5 Nordic Countries. <i>Annals of Surgery</i> , <b>2021</b> , 274, e535-e540  | 7.8  | 7  |

|    |   |      |   |
|----|---|------|---|
| 42 | Phosphorus magnetic resonance spectroscopy of the liver for evaluating inflammation and fibrosis in autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2017</b> , 52, 886-892   | 2.4  | 6 |
| 41 | Value of brush cytology for optimal timing of liver transplantation in primary sclerosing cholangitis. <i>Liver International</i> , <b>2017</b> , 37, 735-742   | 7.9  | 6 |
| 40 | Clostridium difficile infection in patients with inflammatory bowel disease: a case control study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2018</b> , 53, 947-951  | 2.4  | 6 |
| 39 | Outcomes of patients hospitalized with peptic ulcer disease diagnosed in acute upper endoscopy. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2017</b> , 29, 1251-1257  | 2.2  | 6 |
| 38 | Prognostic value of clinical variables and liver histology for development of fibrosis and cirrhosis in autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2017</b> , 52, 321-327   | 2.4  | 6 |
| 37 | Low prevalence of hepatitis C antibodies in chronic liver disease in Finland. <i>Scandinavian Journal of Infectious Diseases</i> , <b>1991</b> , 23, 139-42   |      | 6 |
| 36 | Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1180-1188.e4                                      | 6.9  | 6 |
| 35 | Suspicious brush cytology is an indication for liver transplantation evaluation in primary sclerosing cholangitis. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 6147-6154   | 5.6  | 5 |
| 34 | Inflammatory bowel disease and anemia: intravenous iron treatment. <i>Scandinavian Journal of Gastroenterology</i> , <b>2018</b> , 53, 430-434  | 2.4  | 5 |
| 33 | Health-related quality of life before and after liver transplantation in patients with primary sclerosing cholangitis. <i>Scandinavian Journal of Gastroenterology</i> , <b>2020</b> , 55, 347-353  | 2.4  | 4 |
| 32 | Diclofenac does not reduce the risk of acute pancreatitis in patients with primary sclerosing cholangitis after endoscopic retrograde cholangiography. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 462-471                     | 5.3  | 4 |
| 31 | A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. <i>PLoS ONE</i> , <b>2014</b> , 9, e93601   | 3.7  | 4 |
| 30 | Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection. <i>Hepatology</i> , <b>2011</b> , 53, 1067-8  | 11.2 | 4 |
| 29 | Symptoms, endoscopic findings and histology predicting symptomatic benefit of Helicobacter pylori eradication. <i>Scandinavian Journal of Gastroenterology</i> , <b>2008</b> , 43, 810-6  | 2.4  | 4 |
| 28 | Gastroesophageal reflux patients with defective antioxidative capacity in the proximal esophageal mucosa before antireflux surgery and also after 4-year follow-up. <i>Annals of Medicine</i> , <b>2008</b> , 40, 74-80                               | 1.5  | 4 |
| 27 | Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis. <i>Clinical and Translational Gastroenterology</i> , <b>2021</b> , 12, e00315   | 4.2  | 4 |
| 26 | Impact of paediatric onset primary sclerosing cholangitis on clinical course and outcome of inflammatory bowel disease: a case-control population-based study in Finland. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 984-990 | 2.4  | 3 |
| 25 | THU-251-Metabolic risk factors for advanced liver disease among alcohol risk users in the general population. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e273   | 13.4 | 3 |

|    |  |      |   |
|----|--|------|---|
| 24 | A randomized, controlled study of peginterferon lambda-1a/ribavirin and daclatasvir for hepatitis C virus genotype 2 or 3. <i>SpringerPlus</i> , <b>2016</b> , 5, 1365   |      | 3 |
| 23 | LBP-01-In NAFLD, alcohol drinking habits and genetics predict progression to advanced liver disease: follow-up of population surveys. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e141                        | 13.4 | 2 |
| 22 | Role of Autoimmunity in Patients Transplanted for Acute Liver Failure of Unknown Origin: A Clinical and Graft Biopsy Analysis. <i>Liver Transplantation</i> , <b>2020</b> , 26, 764-773                            | 4.5  | 2 |
| 21 | Nonresponder patients with hepatitis C virus genotype 2/3 infection: a question of low systemic interferon concentrations?. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 50, e22-5                          | 11.6 | 2 |
| 20 | Mortality, Reoperation, and Hospital Stay Within 90 Days of Primary and Secondary Antireflux Surgery in a Population-Based Multinational Study. <i>Gastroenterology</i> , <b>2021</b> , 160, 2283-2290             | 13.3 | 2 |
| 19 | Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease. <i>Liver International</i> , <b>2021</b> , 41, 2590-2600   | 7.9  | 2 |
| 18 | Hospital Volume of Antireflux Surgery in Relation to Endoscopic and Surgical Re-interventions. <i>Annals of Surgery</i> , <b>2021</b> , 274, e1138-e1143   | 7.8  | 1 |
| 17 | REPLY. <i>Hepatology</i> , <b>2020</b> , 71, 1888-1889   | 11.2 | 1 |
| 16 | Chronic cholestasis detection by a novel tool: automated analysis of cytokeratin 7-stained liver specimens. <i>Diagnostic Pathology</i> , <b>2021</b> , 16, 41   | 3    | 1 |
| 15 | Presence of interferon- $\gamma$ , male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 56, 849-854 | 2.4  | 1 |
| 14 | Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile. <i>Hepatology</i> , <b>2021</b> ,   | 11.2 | 1 |
| 13 | Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland. <i>United European Gastroenterology Journal</i> , <b>2021</b> ,   | 5.3  | 1 |
| 12 | Development and validation of a model to predict incident chronic liver disease in the general population: the CLivD score.. <i>Journal of Hepatology</i> , <b>2022</b> ,  | 13.4 | 1 |
| 11 | Biliary hCGIIs a Potential Novel Marker for Prediction of Biliary Neoplasia in Primary Sclerosing Cholangitis Patients. <i>Livers</i> , <b>2021</b> , 1, 322-329   |      | 1 |
| 10 | Noncholesterol Sterols as Surrogate Markers in Patients with Severe Alcoholic Hepatitis. <i>Lipids</i> , <b>2018</b> , 53, 323-334   | 1.6  | 0 |
| 9  | Psychiatric assessment of globus pharyngis patients. <i>Nordic Journal of Psychiatry</i> , <b>1992</b> , 46, 303-306   | 2.3  | 0 |
| 8  | Antireflux surgery and risk of lung cancer by histological type in a multinational cohort study. <i>European Journal of Cancer</i> , <b>2020</b> , 138, 80-88  | 7.5  | 0 |
| 7  | Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C. <i>PLoS ONE</i> , <b>2021</b> , 16, e0251392   | 3.7  | 0 |

|   |  |      |   |
|---|--|------|---|
| 6 | Low serum vitamin D level associated with incident advanced liver disease in the general population - a prospective study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 56, 299-303 | 2.4  | ○ |
| 5 | Use of thiopurines is not a risk factor for post-ERC pancreatitis in patients with primary sclerosing cholangitis. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1020-1027                    | 3.3  | ○ |
| 4 | Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process. <i>Gastroenterology</i> , <b>2021</b> , 161, 1764-1775.e5         | 13.3 | ○ |
| 3 | Reply: To PMID 24519039. <i>Hepatology</i> , <b>2014</b> , 60, 2130-1  | 11.2 |   |
| 2 | Insulin Resistance and Genetic Risk Predict Liver-Related Outcomes and Death in Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , <b>2019</b> , 3, 1704-1705                        | 6    |   |
| 1 | Immunoassay for trypsinogen-4.. <i>Analytical Biochemistry</i> , <b>2022</b> , 114681  | 3.1  |   |